Clinical Report: The Benefits of Intravitreal Steroids During Vitrectomy
Overview
Intravitreal triamcinolone acetonide enhances visualization during vitrectomy and provides postoperative anti-inflammatory effects. A study demonstrated significant improvements in visualization scores following its use.
Background
Intravitreal steroids, particularly triamcinolone acetonide, are critical in vitreoretinal surgery for their ability to suppress inflammation and improve surgical outcomes. The FDA-approved formulation of triamcinolone acetonide is specifically indicated for intraocular use.
Data Highlights
Visualization Score
Before Instillation
After Instillation
Mean Score
0.5
3.7
Key Findings
Triamcinolone acetonide enhances vitreous visualization during vitrectomy.
A study showed a mean visualization score increase from 0.5 to 3.7 after triamcinolone instillation (P<.0001).
83.3% of posterior-segment structures were rated as clearly delineated after instillation.
Optimal dilution ratios for triamcinolone use range from 8:1 to 12:1 with balanced salt solution.
Preserved triamcinolone (Kenalog) poses risks of retinal toxicity and inflammation.
Triesence is the only FDA-approved, preservative-free formulation for intraocular use.
Clinical Implications
Surgeons should consider using diluted triamcinolone acetonide during vitrectomy. Careful attention to dilution and injection technique is essential.
Conclusion
Intravitreal triamcinolone acetonide serves as an adjunct in vitrectomy, improving visualization.
Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.
